期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Chronic hepatitis C:This and the new era of treatment 被引量：10

Chronic hepatitis C:This and the new era of treatment
下载PDF
导出
摘要 Over the last years it has started a real revolution in the treatment of chronic hepatitis C. This occurred for the availability of direct-acting antiviral agents that allow to reach sustained virologic response in approximately 90% of cases. In the near future further progress will be achieved with the use of pan-genotypic drugs with high efficacy but without side effects. Over the last years it has started a real revolution in the treatment of chronic hepatitis C. This occurred for the availability of direct-acting antiviral agents that allow to reach sustained virologic response in approximately 90% of cases. In the near future further progress will be achieved with the use of pan-genotypic drugs with high efficacy but without side effects.
作者 Gaetano Bertino Annalisa Ardiri Maria Proiti Giuseppe Rigano Evelise Frazzetto Shirin Demma MariaIrene Ruggeri Laura Scuderi Giulia Malaguarnera Nicoletta Bertino Venerando Rapisarda Isidoro Di Carlo Adriana Toro Federico Salomone Mariano Malaguarnera Emanuele Bertino Michele Malaguarnera
机构地区 Hepatology Unit-Department of Clinical and Experimental Medicine Internal Medicine Unit Research Centre“La Grande Senesce” Department of Biomedical Sciences Faculty of Pharmacy Occupational Medicine Unit Department of Surgical Sciences Gastroenterology Unit
出处 《World Journal of Hepatology》 CAS 2016年第2期92-106,共15页 世界肝病学杂志（英文版）（电子版）
关键词 Direct-acting ANTIVIRAL AGENTS Nucleosideinhibitors BOCEPREVIR Sofosbuvir TELAPREVIR HEPATITISC Simeprevir Daclatasvir Ledipasvir Faldaprevir Ritonavir Ombitasvir Dasabuvir Direct-acting antiviral agents Nucleoside inhibitors Boceprevir Sofosbuvir Telaprevir Hepatitis C Simeprevir Daclatasvir Ledipasvir Faldaprevir Ritonavir Ombitasvir Dasabuvir
分类号 R512.63 [医药卫生—内科学]
  • 相关文献

参考文献2

二级参考文献49

  • 1Simona Bota,Ioan Sporea,Roxana Sirli,Alina Popescu,Adriana Maria Neghinǎ,Mirela Dǎnilǎ,Mihnea Strǎin.Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review[J].World Journal of Hepatology,2013,5(3):120-126. 被引量：6
  • 2Di Fazio I, Motta M, Musumeci S, Neri S, Pistone G, Malaguarnera M. Efficacy of human recombinant erythropoietin plus IFN-alpha in patients affected by chronic hepatitis C. J Interferon Cytokine Res 2004; 24:594-599.
  • 3El-Beshlawy A, El Accaoui R, Abd El-Sattar M, Gamal El- Deen MH, Youssry I, Shaheen N, Hamdy M, El-Ghamrawy M, Taher A. Effect of L-carnitine on the physical fitness of thalassemic patients. Ann Hemato12007; 86:31-34.
  • 4Yesilipek MA, Yegin O. Interferon-alpha therapy for refractory idiopathic thrombocytopenic purpura in children. Turk J Pediatr 1997; 39:173-176.
  • 5Palmieri L, Ronca F, Malengo S, Bertelli A. Protection of beta-thalassaemic erythrocytes from oxidative stress by propionyl carnitine. Int J Tissue React 1994; 16:121-129.
  • 6Metal A, Tuncel P, Surmen-Gur E, Ozbek R, Ozturk E, Gunay U. Lipid peroxidation and antioxidant status in beta- thalassemia. Pediatr Hematol Oncol 2000; 17:687-693.
  • 7Al-Quobaili FA, Abou Asali IE. Serum levels of lipids and lipoproteins in Syrian patients with beta-thalassemia major. Saudi Med J 2004; 25:871-875.
  • 8Trovato GM, Ginardi V, Di Marco V, Dellaira AE, Corsi M. Long-term 1-carnitine treatment of chronic anaemia of patients with end-stage renal disease. Curr Ther Res Clin Exp 1982; 31:1042-1049.
  • 9Matsumura M, Hatakeyama S, Koni I, Mabuchi H, Muramoto H. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephton 1996; 72:574-578.
  • 10Watanabe H, Kobayashi A, Hayashi H, Yamazaki N. Effects of long-chain acyl carnitine on membrane fluidity of human erythrocytes. Biochim Biophys Acta 1989; 980:315-318.

共引文献5

同被引文献444

  • 1Yu-Jing Zhang.在 hepatocellular 癌的化学致癌物和基因变化的相互作用[J].World Journal of Hepatology,2010,2(3):94-102. 被引量：1
  • 2Michael.达人巴黎行[J].网球大师,2013,0(6):100-102. 被引量：10
  • 3H Le Guillou-Guillemette,S Vallet,C Gaudy-Graffin,C Payan,A Pivert,A Goudeau,F Lunel-Fabiani.Genetic diversity of the hepatitis C virus: Impact and issues inthe antiviral therapy[J].World Journal of Gastroenterology,2007,13(17):2416-2426. 被引量：6
  • 4Argentini, Claudio,Genovese, Domenico,Dettori, Stefano,Rapicetta, Maria.HCV genetic variability: from quasispecies evolution to genotype classification[J]. Future Microbiology . 2009 (3)
  • 5Satarug, Soisungwan,Garrett, Scott H,Sens, Mary Ann,Sens, Donald A.Cadmium, Environmental Exposure, and Health Outcomes[J]. Environmental Health Perspectives . 2010 (2)
  • 6Ralf Bartenschlager,Francois Penin,Volker Lohmann,Patrice André.Assembly of infectious hepatitis C virus particles[J].Trends in Microbiology.2010(2)
  • 7Virginia Hernandez–Gea,Sara Toffanin,Scott L. Friedman,Josep M. Llovet.Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma[J].Gastroenterology.2013(3)
  • 8Giovanna Fattovich,Tommaso Stroffolini,Irene Zagni,Francesco Donato.Hepatocellular carcinoma in cirrhosis: Incidence and risk factors[J].Gastroenterology.2004(5)
  • 9Gaetano Bertino,Isidoro Di Carlo,Annalisa Ardiri,Giuseppe Stefano Calvagno,Shirin Demma,Giulia Malaguarnera,Nicoletta Bertino,Mariano Malaguarnera,Adriana Toro,Michele Malaguarnera.Systemic therapies in hepatocellular carcinoma: present and future[J].Future Oncol.2013(10)
  • 10Igor P. Pogribny,Ivan Rusyn.Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma[J].Cancer Letters.2012

引证文献10

二级引证文献47

World Journal of Hepatology
2016年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部